Hshieh Tammy T, Chapin Benjamin A, Mak Wingyun, Xu Guoquan, Schmitt Eva M, Marcantonio Edward R, Shanes Hannah, Heine Cole, Helfand Jordan, Price Catherine, Boockvar Kenneth S, Metzger Eran D, Fong Tamara G, Jones Richard N, Inouye Sharon K
Hebrew SeniorLife, Hinda and Arthur Marcus Institute for Aging Research, Boston, MA, USA.
Brigham and Women's Hospital, Division of Aging, Department of Medicine, Boston, MA, USA.
J Geriatr Psychiatry Neurol. 2025 May 16:8919887251343604. doi: 10.1177/08919887251343604.
PurposeDelirium is a common yet preventable complication of hospitalization, surgery and illness that is associated with poor outcomes. Older adults with Alzheimer's Disease and Related Dementias (ADRD) are especially vulnerable to delirium and experience greater delirium severity, yet no existing assessment tool is specifically designed to evaluate this vulnerable population. This study will validate two new delirium severity instruments, the Delirium Severity (DEL-S) rating for all older adults and the Delirium Severity Rating in ADRD (DEL-S-AD) for patients with dementia.Design/Setting and ParticipantsThe Better ASsessment of ILlness II (BASIL II) study is an innovative prospective cohort study that measures cognitive function, delirium, delirium severity, demographics, clinical and functional variables and clinical outcomes. Participants include older adults from 3 unique yet complementary clinical sites: medical inpatients, elective surgery inpatients, or skilled nursing facility residents.MethodsPerformance of DEL-S and DEL-S-AD items in older adults with cognition ranging from no impairment to moderate impairment will be determined. Analyses will include psychometric characteristics of DEL-S and DEL-S-AD items, harmonization of the two scales and validation against reference standard diagnoses.Conclusions and ImplicationsResults from this study will help accurately measure delirium severity, a critically important, graded outcome. The DEL-S-AD instrument holds broad applications in persons with and without ADRD to monitor delirium severity in clinical settings, and as an outcome measure in future clinical treatment trials and pathophysiologic studies. Ultimately, the DEL-S and DEL-S-AD have the potential to improve health care for the vulnerable, growing population of older adults with cognitive impairment worldwide.
目的
谵妄是住院、手术和疾病常见但可预防的并发症,与不良预后相关。患有阿尔茨海默病及相关痴呆症(ADRD)的老年人尤其易患谵妄,且谵妄严重程度更高,但目前尚无专门设计用于评估这一脆弱人群的评估工具。本研究将验证两种新的谵妄严重程度评估工具,即适用于所有老年人的谵妄严重程度(DEL-S)评分,以及适用于痴呆症患者的ADRD谵妄严重程度评分(DEL-S-AD)。
设计/设置与参与者
疾病更好评估II(BASIL II)研究是一项创新性前瞻性队列研究,测量认知功能、谵妄、谵妄严重程度、人口统计学、临床和功能变量以及临床结局。参与者包括来自3个独特但互补临床场所的老年人:内科住院患者、择期手术住院患者或熟练护理机构居民。
方法
将确定DEL-S和DEL-S-AD项目在认知功能从无损害到中度损害的老年人中的表现。分析将包括DEL-S和DEL-S-AD项目的心理测量特征、两种量表的协调以及对照参考标准诊断进行验证。
结论与意义
本研究结果将有助于准确测量谵妄严重程度,这是一个至关重要的分级结局。DEL-S-AD工具在有或没有ADRD的人群中具有广泛应用,可在临床环境中监测谵妄严重程度,并作为未来临床治疗试验和病理生理学研究的结局指标。最终,DEL-S和DEL-S-AD有可能改善全球认知受损的脆弱老年人群的医疗保健。